Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 2/20 | 0.55 |
| ▸ | CDK8 | P49336 | 8/20 | 0.53 |
| ▸ | AXL | P30530 | 2/20 | 0.53 |
| ▸ | CDK7 | P50613 | 2/20 | 0.52 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.52 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.52 |
| ▸ | CDK1 | P06493 | 2/20 | 0.52 |
| ▸ | FES | P07332 | 2/20 | 0.52 |
| ▸ | ROS1 | P08922 | 2/20 | 0.52 |
| ▸ | FER | P16591 | 2/20 | 0.52 |
| ▸ | FLT4 | P35916 | 2/20 | 0.52 |
| ▸ | KDR | P35968 | 2/20 | 0.52 |
| ▸ | IRAK1 | P51617 | 2/20 | 0.52 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.52 |
| ▸ | PKN2 | Q16513 | 2/20 | 0.52 |
| ▸ | MARK2 | Q7KZI7 | 2/20 | 0.52 |
| ▸ | MINK1 | Q8N4C8 | 2/20 | 0.52 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.52 |
| ▸ | SLK | Q9H2G2 | 2/20 | 0.52 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Formamide SCHEMBL27890827 | 0.92 | RIPK1 (0.52) | RIPK1CDK8AXLCDK7MAP4K4 | |
| Acetamide SCHEMBL27710907 | 0.92 | RIPK1 (0.56) | RIPK1CDK8AXLCDK7MAP4K4 | |
| Trifluoroacetic Acid SCHEMBL4751915 | 0.91 | RIPK1 (0.48) | RIPK1CDK8AXLCDK7MAP4K4 | |
| SCHEMBL27732330 | 0.87 | RIPK1 (0.56) | RIPK1CDK8AXLCDK7MAP4K4 | |
| SCHEMBL29378344 | 0.84 | RIPK1 (0.70) | RIPK1CDK8AXLCDK7MAP4K4 | |
| SCHEMBL4117054 | 0.84 | RIPK1 (0.70) | RIPK1CDK8AXLCDK7MAP4K4 | |
| SCHEMBL12410716 | 0.84 | CDK8 (0.67) | RIPK1CDK8AXLCDK7MAP4K4 | |
| SCHEMBL4344288 | 0.83 | CDK8 (0.55) | RIPK1CDK8AXLCDK7MAP4K4 | |
| Hydrochloric Acid SCHEMBL27706353 | 0.83 | RIPK1 (0.68) | RIPK1CDK8AXLCDK7MAP4K4 | |
| SCHEMBL415994 | 0.81 | CDK8 (0.68) | RIPK1CDK8CDK7MAP4K4CHEK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 399 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025038910-A1 | CRYSTALLINE POLYMORPH FORM A OF A JAK INHIBITOR AND METHODS FOR ITS PREPARATION | ACLARIS THERAPEUTICS, INC. (US) | 2025-02-20 | — | — | WO | claimed |
| CN-111048415-B | Selective etching liquid composition and preparation method and application thereof | 上海新阳半导体材料股份有限公司 | 2023-03-14 | — | — | CN | claimed |
| EP-3807274-B1 | 4-SUBSTITUTED PYRROLO[2,3-B]PYRIDINE AS ERBB MODULATORS USEFUL FOR TREATING CANCER | LEAD DISCOVERY CENTER GMBH (DE) | 2022-07-27 | — | — | EP | claimed |
| US-20190209536-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2019-07-11 | — | — | US | claimed |
| US-20170319559-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2017-11-09 | — | — | US | claimed |
| US-20170056382-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2017-03-02 | — | — | US | claimed |
| EP-2318367-B1 | PIPERIDINE AND PYRROLIDINE COMPOUNDS | ACTELION PHARMACEUTICALS LTD (CH) | 2013-03-20 | — | — | EP | claimed |
| CN-102015645-B | Piperidine and pyrrolidine compounds | ACTELION PHARMACEUTICALS LTD | 2012-11-14 | — | — | CN | claimed |
| CN-102015645-A | Piperidine and pyrrolidine compounds | ACTELION PHARMACEUTICALS LTD | 2011-04-13 | — | — | CN | claimed |
| WO-2009133522-A1 | PIPERIDINE AND PYRROLIDINE COMPOUNDS | ACTELION PHARMACEUTICALS LTD (CH) | 2009-11-05 | — | — | WO | claimed |
| EP-1165514-A1 | 3-(ANILINOMETHYLENE) OXINDOLES AS PROTEIN TYROSINE KINASE AND PROTEIN SERINE/THREONINE KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2002-01-02 | — | — | EP | claimed |
| WO-2000056710-A1 | 3-(ANILINOMETHYLENE) OXINDOLES AS PROTEIN TYROSINE KINASE AND PROTEIN SERINE/THREONINE KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2000-09-28 | — | — | WO | claimed |
| EP-3710428-B1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2026-03-25 | — | — | EP | disclosed |
| US-12577243-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2026-03-17 | — | — | US | disclosed |
| EP-3856178-B1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2026-03-11 | — | — | EP | disclosed |
| US-20260062410-A1 | SUBSTITUTED PYRROLOPYRIDINE JAK INHIBITORS AND METHODS OF MAKING AND USING THE SAME | ACLARIS THERAPEUTICS INC (US) | 2026-03-05 | — | — | US | disclosed |
| EP-1180105-A2 | SUBSTITUTED AZA-OXINDOLE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2002-02-20 | — | — | EP | disclosed |
| EP-1165514-A1 | 3-(ANILINOMETHYLENE) OXINDOLES AS PROTEIN TYROSINE KINASE AND PROTEIN SERINE/THREONINE KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2002-01-02 | — | — | EP | disclosed |
| WO-2000056710-A1 | 3-(ANILINOMETHYLENE) OXINDOLES AS PROTEIN TYROSINE KINASE AND PROTEIN SERINE/THREONINE KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2000-09-28 | — | — | WO | disclosed |
| WO-2000055159-A2 | SUBSTITUTED AZA-OXINDOLE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2000-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12577243-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, FAAH | RIPK1 3954/4885CDK8 4037/4885AXL 3890/4885 |
| US-20260062410-A1 | SUBSTITUTED PYRROLOPYRIDINE JAK INHIBITORS AND METHODS OF MAKING AND USING THE SAME | JAK3, JAK1, JAK2 | RIPK1 404/4885CDK8 603/4885AXL 1887/4885 |
| US-20190209536-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | RIPK1 507/4885CDK8 56/4885AXL 1354/4885 |
| US-20170319559-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | RIPK1 507/4885CDK8 56/4885AXL 1354/4885 |
| US-20170056382-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | RIPK1 507/4885CDK8 56/4885AXL 1354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.